Metabolic signature of obesity-associated insulin resistance and type 2 diabetes
| Autor: | Mohamed A. Elrayess, Alexander Dömling, Maha V. Agha, Ilhame Diboun, Fatima F. S. Mohamed, Nayef Mazloum, Stephen L. Atkin, Haya Al-Sulaiti |
|---|---|
| Přispěvatelé: | Drug Design, Medicinal Chemistry and Bioanalysis (MCB) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty medicine.medical_treatment lcsh:Medicine Pilot Projects 030209 endocrinology & metabolism Type 2 diabetes Lower risk General Biochemistry Genetics and Molecular Biology Translational Research Biomedical Young Adult 03 medical and health sciences chemistry.chemical_compound Liver disease 0302 clinical medicine Insulin resistance Internal medicine Blood metabolites Type 2 diabetes mellitus medicine Animals Humans Choline Metabolomics Obesity Phospholipids business.industry Research Insulin lcsh:R Type 2 Diabetes Mellitus General Medicine Middle Aged medicine.disease Insulin sensitivity 030104 developmental biology Endocrinology Diabetes Mellitus Type 2 chemistry Disease Progression Metabolome Female business Biomarkers |
| Zdroj: | Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-11 (2019) Journal of Translational Medicine Journal of translational medicine, 17(1):348. BioMed Central Ltd. |
| ISSN: | 1479-5876 |
| DOI: | 10.1186/s12967-019-2096-8 |
| Popis: | Background Obesity is associated with an increased risk of insulin resistance and type 2 diabetes mellitus (T2DM). However, some obese individuals maintain their insulin sensitivity and exhibit a lower risk of associated comorbidities. The underlying metabolic pathways differentiating obese insulin sensitive (OIS) and obese insulin resistant (OIR) individuals remain unclear. Methods In this study, 107 subjects underwent untargeted metabolomics of serum samples using the Metabolon platform. Thirty-two subjects were lean controls whilst 75 subjects were obese including 20 OIS, 41 OIR, and 14 T2DM individuals. Results Our results showed that phospholipid metabolites including choline, glycerophosphoethanolamine and glycerophosphorylcholine were significantly altered from OIS when compared with OIR and T2DM individuals. Furthermore, our data confirmed changes in metabolic markers of liver disease, vascular disease and T2DM, such as 3-hydroxymyristate, dimethylarginine and 1,5-anhydroglucitol, respectively. Conclusion This pilot data has identified phospholipid metabolites as potential novel biomarkers of obesity-associated insulin sensitivity and confirmed the association of known metabolites with increased risk of obesity-associated insulin resistance, with possible diagnostic and therapeutic applications. Further studies are warranted to confirm these associations in prospective cohorts and to investigate their functionality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |